

PROVIDER Update



CONTRACTUAL | JANUARY 2, 2026 | UPDATE 26-016 | 6 PAGES

4th Quarter 2025 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after March 10, 2026

The Health Net* Pharmacy Advisory Committee approved updates to the Injectable Medication HCPCS/Division of Financial Responsibility (DOFR) Crosswalk on November 25, 2025. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, **effective March 10, 2026**, are listed on pages 2–6 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.

The update includes:

- 21 **new injectable** medications to be added to the crosswalk
- 21 **updates and changes** to current injectable medication procedure codes
- 8 **new biosimilars** and updates to be added to the crosswalk
- 7 **new generic** drugs
- 3 **category** changes

Need help? Contact us

Relevant sections of Health Net’s provider operations manuals will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library under Quick Links*, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer Group
 - HMO/POS
 - PPO
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP

Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP

Ambetter PPO – 844-463-8188

Health Net Employer Group

HMO, POS & PPO – 800-641-7761

Medi-Cal (including CS and ECM providers)

– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

*Health Net of California, Inc. and Health Net Community Solutions, Inc. are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

New injectable medications to be added to the Injectable Medication HCPCS/DOFR Crosswalk

The following medications have been approved as additions to the crosswalk reference table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
90288	BabyBIG®	Botulism immune globulin, human, for intravenous use	Therapeutic injection	
90287	Botulism antitoxin heptavalent	Botulinum antitoxin, equine, any route	Therapeutic injection	
J9999	Blenrep®	Belantamab mafodotin-blmf for intravenous (IV) solution, 70 mg	Therapeutic injection	Chemotherapy ¹
J3490	Brekiya®	Dihydroergotamine mesylate solution auto-injector, 1 mg/mL	Self-injectable	
J0577	Brixadi® weekly	Injection, buprenorphine extended-release, less than or equal to 7 days of therapy	Therapeutic injection	
J3490	Dawnzera™	Donidalorsen sodium subcutaneous solution auto-injector, 80 mg/0.8 mL	Self-injectable	
J7177	Fibryga®	Fibrinogen concentrate (human) for IV solution, 2 gm	Therapeutic injection	
J3490	Forzinity™	Elamipretide HCL subcutaneous solution, 280 mg/3.5 mL	Self-injectable	
J1612	Gvoke®	Injection, glucagon, 0.01 mg	Self-injectable	
90371	Hyperhep B®	Hepatitis B immune globulin (HBIG), human, for intramuscular use	Therapeutic injection	
C9399	Keytruda QLEX™	Pembrolizumab-berahyaluron-pmph injection	Therapeutic injection	Chemotherapy ¹
J3490	Leqembi® IQLK™	Lecanemab-irmb solution auto-injector, 360 mg/1.8 mL	Self-injectable	
91304	Nuvaxovid™	COVID-19 vaccine, adjuvanted	Therapeutic injection	Immunization
J3590	Papzimeos™	Zopapogene imadenovec-drba	Therapeutic injection	
90384	RhoGAM® ultra-filtered plus	Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use	Therapeutic injection	
91322	Spikevax®	COVID-19 vaccine, mRNA	Therapeutic injection	Immunization

New injectable medications to be added to the Injectable Medication HCPCS/DOFR Crosswalk,
continued

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Yimmugo®	Immune Globulin (Human)-dira IV solution, 10 gm/100 mL	Therapeutic injection	
J3490	Zurnai™	Nalmefene HCl solution auto-injector, 1.5 mg/0.5 mL (base equivalent)	Self-injectable	
J3490	Zegalogue®	Dasiglucagon injection, for subcutaneous use	Self-injectable	
J0681	Zevtera®	Injection, ceftobiprole medocartil sodium, 3 mg	Therapeutic injection	Home health/infusion ²
J0668	Zynrelef®	Bupivacaine and meloxicam extended-release solution	Therapeutic injection	

Updates/changes to current injectable medication procedure codes or HCPCS codes

Updates to the Injectable Medication HCPCS/DOFR Crosswalk are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk reference table.

HCPCS	Drug name	Generic name	Comment
J9215	Alferon N®	Interferon alfa-N3 (human leukocyte derived), 250,000 IU injection	No longer manufactured
J0457	Azactam®	Injection, aztreonam, 100 mg	Replaces S0073
J0515	Benztropine	Benztropine (brand name, formerly, Cogentin®) mesylate injection, 1 mg	The brand-name Cogentin has been discontinued
J3490	Bydureon®	Exenatide extended release	No longer manufactured
J3490	Bydureon® BCise	Exenatide extended release injectable suspension, 2 mg	No longer manufactured
J0636	Calcijex®	Injection, calcitriol, 0.1 mcg	Brand has been discontinued; a generic version is available
91320	Comirnaty® 2024-2025	Covid-19 Vaccine, mRNA, 24-25 Formula	No longer manufactured
J0802	Cortrophin gel	Injection, corticotropin (animal-based), up to 40 units	Additional manufacturer
J0759	Cleviprex®	Clevidipine butyrate, 1 mg	Replaces C9248

Updates/changes to current injectable medication procedure codes or HCPCS codes, *continued*

HCPCS	Drug name	Generic name	Comment
C9306	Emrelis™	Telisotuzumab vedotin-tllv for injection, for IV use	Replaces J9999
J3403	Encelto™	Revakinagene taroretcel-lwey intravitreal implant 200,000 cells	Replaces J3402
J0139	Humira® (2 pen)	Injection, adalimumab, 1 mg	Code added
J0641	Fusilev®	Levoleucovorin calcium, 0.5 mg	Brand has been discontinued; a generic version is available
C9305	Imaavy™	Nipocalimab-Aahu IV solution	Replaces J3590
J9065	Leustatin®	Cladribine per 1 mg	No longer manufactured
J3490	Lusedra®	Fospropofol disodium Injection	No longer manufactured
J2151	Mannitol	Mannitol injection	Replaces J2150
J7174	Qfitlia™	Fitusiran injection, for subcutaneous use	Replaces J3490
J0900	Valertest #1	Testosterone enanthate and estradiol valerate	No longer manufactured
90625	Vaxchora®	Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use	This oral suspension will be discontinued
J0740	Vistide®	Cidofovir, 375 mg injection	Brand has been discontinued; a generic version is available

New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk

The following medications have been approved as additions to the crosswalk reference table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Bilprevda®	Denosumab-nxxp injection, for subcutaneous use biosimilar to Xgeva®	Therapeutic injection	Chemotherapy adjunctive ¹
J3590	Bildyos®	Denosumab-nxxp injection, for subcutaneous use biosimilar to Prolia®	Therapeutic injection	
J3590	Jobevne™	Bevacizumab-nwgd, biosimilar to Avastin®	Therapeutic injection	

New biosimilars added to the Injectable Medication HCPCS/DOFR Crosswalk, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q5134	Tyruko®	Natalizumab-sztnm, biosimilar to TYSABRI®	Therapeutic injection	
J3590	Starjemza™	Ustekinumab-hmny IV solution, 130 mg/26 mL (5 mg/mL) (for IV infusion), biosimilar to Stelara®	Therapeutic injection	
J3590	Starjemza™	Ustekinumab-hmny solution prefilled syringe, 45 mg/0.5 mL, biosimilar to Stelara	Self-injectable	
J3590	Starjemza™	Ustekinumab-hmny subcutaneous solution, 45 mg/0.5 mL, biosimilar to Stelara	Self-injectable	

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J0163	Epinephrine	Injection, epinephrine in sodium chloride (endovenous administration), 0.1 mg	Therapeutic injection	
J0164	Epinephrine	Injection, epinephrine in sodium chloride (Baxter), 0.1 mg	Therapeutic injection	
J0462	Atropine sulfate	Injection, atropine sulfate, not therapeutically equivalent to J0461, 0.01 mg	Therapeutic injection	
J0675	Carboprost	Injection, carboprost tromethamine, 0.1 mg	Therapeutic injection	
J1370	Esomeprazole sodium	Injection, esomeprazole sodium, 1 mg	Therapeutic injection	
J2290	Nafcillin	Injection, nafcillin sodium, 20 mg	Therapeutic injection	Home health/infusion ²
J0582	Bivalirudin	Injection, bivalirudin (endovenous administration), not therapeutically equivalent to J0583, 1 mg	Therapeutic injection	

Category changes

The following medications have been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3490	Saxenda®	Liraglutide (weight management) solution pen-injector, 6 mg/mL	Self-injectable	
J3490	Victoza®	Liraglutide [rDNA origin] injection	Self-injectable	
J3490	Saxenda®	Liraglutide (weight management) solution pen-injector, 6 mg/mL	Self-injectable	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/alpha-numeric.